

Attorney Docket No.:E3691-00102
PATENT

REMARKS

Preliminary to the examination of the above-captioned application, Applicants respectfully requests entry of the amendments and following remarks into the file history of the application.

Claims 84-128 have been cancelled without prejudice, and new claims 129-171 are added herein. As such, claims 129-171 are now pending.

Basis and support for new claims 129-171 can be found throughout the specification as originally filed, including the claims, drawings, and examples. No new matter has been added.

For new claims 129-145, see, for example, descriptions of doses at pages 14, 16, 18, 19, and 77 of the specification (International Publication Number WO 2004/017956). Acid addition salts of triethylenetetramine and succinic acid are described, for example, at page 30. Support for pharmaceutically acceptable carriers is found, for example, at pages 20, 30, 45, 49, 59, 64, 67, and 69. Support for compositions comprising a pharmaceutically acceptable carrier and an acid addition salt of triethylenetetramine and succinic acid, including purified compounds, are found throughout the specification.

Support for oral administration including, for example, by tablet, capsule, enteric-coated tablet, and layered tablets, and oral administration using sustained release preparations including, for example, delayed release preparations, slow release preparation, controlled release preparations, and extended release preparations in new claims 147-156 is found, for example, at pages 43, 46-48, 50-54, 56-62 and 65. Support for transdermal administration, transmucosal administration, and the use of pharmaceutical forms suitable for administration as a suppository in new claims 157-159 is found, for example, at pages 43, 48 and 62-65.

Support for use of a delivery agent to enhance entry to the systemic circulation following oral administration, including the use of vasodilators and reverse active transport agents in new claims 160 and 161, is found, for example, at pages 76-77.

Support for treatment of diabetes in new claims 162-164 is found, for example, at pages 8, 9, 10, 15, 17, 27, 28, 44, 72, 79, 86-88, 92, 94, 95, 96, 98, and 100-102. Support for treatment of acute coronary syndrome in new claims 167 and 168 is found, for example, at pages 13, 15, 17, 22, 30 and 44. Support for treatment of cardiomyopathy, myocardial infarction, and myocarditis in new claims 165, 166, 169, and 170 is found, for example, at pages 9, 15, 17, 44, 88, and 89. Support for treatment to prevent or ameliorate tissue damage

Attorney Docket No.:E3691-00102
PATENT

in a subject that does not have Wilson's disease in new claim 171 is found throughout the specification including, for example, at pages 10, 29, 46, and 98.


CONCLUSION

Applicants respectfully submit that all pending claims are in condition for allowance and requests entry of this Preliminary Amendment and the above Remarks.

Commissioner is hereby authorized to charge the requisite fees, or any fees in connection with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 04-1679.

Respectfully submitted,

By:


James W. Collett, Ph.D.
Reg. No. 46,636

DUANE MORRIS LLP
101 West Broadway, Suite 900
San Diego, CA 92101
(PH) 619.744.2251
(F) 619.744.2201